Ziprasidone D8
(Synonyms: 齐拉西酮-D8,CP-88059 D8) 目录号 : GC37969An internal standard for the quantification of ziprasidone
Cas No.:1126745-58-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Ziprasidone-d8 is intended for use as an internal standard for the quantification of ziprasidone by GC- or LC-MS. Ziprasidone is an atypical antipsychotic.1 It is an agonist of the serotonin (5-HT) receptor subtype 5-HT1A (EC50 = 36.31 nM for inhibition of forskolin-induced adenylate cyclase activity in HeLa cells expressing human receptors), as well as an inverse agonist of 5-HT1D receptors (IC50 = 2.69 nM) and a partial agonist of 5-HT1B receptors (EC50 = 6.17 nM) in [35S]GTPγS binding assays.2,3 Ziprasidone is an antagonist at 5-HT2A and dopamine D2 receptors (Kis = 1.15 and 1.29 nM, respectively) in cell-based assays.4 It inhibits d-amphetamine-induced hyperactivity and apomorphine-induced stereotypy in rats (ID50s = 1.53 and 2.43 mg/kg, respectively). Formulations containing ziprasidone have been used in the treatment of schizophrenia and bipolar I disorder.
1.Seeman, P.Atypical antipsychotics: Mechanism of actionCan. J. Psychiatry47(1)27-38(2002) 2.Schmidt, A.W., Lebel, L.A., Howard, H.R., Jr., et al.Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profileEur. J. Pharmacol.425(3)197-201(2001) 3.Audinot, V., Newman-Tancredi, A., Cussac, D., et al.Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)1B and h5-HT1D receptorsNeuropsychopharmacology25(3)410-422(2001) 4.Seeger, T.F., Seymour, P.A., Schmidt, A.W., et al.Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activityJ. Pharmacol. Exp. Ther.275(1)101-113(1995)
| Cas No. | 1126745-58-1 | SDF | |
| 别名 | 齐拉西酮-D8,CP-88059 D8 | ||
| Canonical SMILES | O=C1CC2=CC(CCN(C([2H])([2H])C3([2H])[2H])C([2H])([2H])C([2H])([2H])N3C4=NSC5=C4C=CC=C5)=C(Cl)C=C2N1 | ||
| 分子式 | C21H13D8ClN4OS | 分子量 | 420.98 |
| 溶解度 | DMSO: slightly soluble,Methanol: slightly soluble | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.3754 mL | 11.877 mL | 23.7541 mL |
| 5 mM | 0.4751 mL | 2.3754 mL | 4.7508 mL |
| 10 mM | 0.2375 mL | 1.1877 mL | 2.3754 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。